Literature DB >> 20585007

Prognosis of pulmonary arterial hypertension: the power of clinical registries of rare diseases.

Vallerie V McLaughlin, Samy Suissa.   

Abstract

Entities:  

Mesh：

Year:  2010        PMID： 20585007     DOI： 10.1161/CIRCULATIONAHA.110.963983

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  11 in total

Review 1.  Pulmonary arterial hypertension: the clinical syndrome.

Authors:  Yen-Chun Lai; Karin C Potoka; Hunter C Champion; Ana L Mora; Mark T Gladwin
Journal:  Circ Res       Date:  2014-06-20       Impact factor: 17.367

2.  Inhaled combination of sildenafil and rosiglitazone improves pulmonary hemodynamics, cardiac function, and arterial remodeling.

Authors:  Jahidur Rashid; Eva Nozik-Grayck; Ivan F McMurtry; Kurt R Stenmark; Fakhrul Ahsan
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-10-11       Impact factor: 5.464

3.  Motivations of patients with pulmonary arterial hypertension to participate in randomized clinical trials.

Authors:  Ricki Carroll; Jules Antigua; Darren Taichman; Harold Palevsky; Paul Forfia; Steven Kawut; Scott D Halpern
Journal:  Clin Trials       Date:  2012-03-02       Impact factor: 2.486

4.  Survival in pulmonary arterial hypertension: A brief review of registry data.

Authors:  Sunil Pauwaa; Roberto F Machado; Ankit A Desai
Journal:  Pulm Circ       Date:  2011 Jul-Sep       Impact factor: 3.017

5.  Baseline Characteristics of the Korean Registry of Pulmonary Arterial Hypertension.

Authors:  Wook-Jin Chung; Yong Bum Park; Chan Hong Jeon; Jo Won Jung; Kwang-Phil Ko; Sung Jae Choi; Hye Sun Seo; Jae Seung Lee; Hae Ok Jung
Journal:  J Korean Med Sci       Date:  2015-09-12       Impact factor: 2.153

6.  Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study.

Authors:  J Gerry Coghlan; Richard Channick; Kelly Chin; Lilla Di Scala; Nazzareno Galiè; Hossein-Ardeschir Ghofrani; Marius M Hoeper; Irene M Lang; Vallerie McLaughlin; Ralph Preiss; Lewis J Rubin; Gérald Simonneau; Olivier Sitbon; Victor F Tapson; Sean Gaine
Journal:  Am J Cardiovasc Drugs       Date:  2018-02       Impact factor: 3.571

7.  Which prognostic factors should be used in pulmonary arterial hypertension in elderly patients?

Authors:  Bahri Akdeniz; Ebru Ozpelit
Journal:  J Geriatr Cardiol       Date:  2017-01       Impact factor: 3.327

8.  Should we use the oral selective IP receptor agonist selexipag off-label in children with pulmonary arterial hypertension?

Authors:  Martin Koestenberger; Georg Hansmann
Journal:  Pulm Circ       Date:  2018 Jul-Sep       Impact factor: 3.017

9.  Pulmonary hypertension in Portugal: first data from a nationwide registry.

Authors:  Rui Baptista; José Meireles; Ana Agapito; Graça Castro; António Marinho da Silva; Teresa Shiang; Fabienne Gonçalves; Susana Robalo-Martins; António Nunes-Diogo; Abílio Reis
Journal:  Biomed Res Int       Date:  2013-10-21       Impact factor: 3.411

10.  Reversal of MicroRNA Dysregulation in an Animal Model of Pulmonary Hypertension.

Authors:  Igor B Gubrij; Amanda K Pangle; Li Pang; Larry G Johnson
Journal:  PLoS One       Date:  2016-01-27       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.